Free Trial
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

CytomX Therapeutics logo
$0.60 +0.02 (+2.93%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytomX Therapeutics Stock (NASDAQ:CTMX)

Key Stats

Today's Range
$0.56
$0.61
50-Day Range
$0.58
$0.94
52-Week Range
$0.56
$5.85
Volume
383,474 shs
Average Volume
2.62 million shs
Market Capitalization
$47.82 million
P/E Ratio
3.53
Dividend Yield
N/A
Price Target
$5.02
Consensus Rating
Moderate Buy

Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Remove Ads

CytomX Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

CTMX MarketRank™: 

CytomX Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 148th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytomX Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about CytomX Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CytomX Therapeutics is 3.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CytomX Therapeutics is 3.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.37.

  • Read more about CytomX Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.37% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 91.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CytomX Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytomX Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.37% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 91.49%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CytomX Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,968.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of CytomX Therapeutics is held by insiders.

  • Percentage Held by Institutions

    67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CytomX Therapeutics' insider trading history.
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
CytomX Therapeutics participates in a conference call with JPMorgan
See More Headlines

CTMX Stock Analysis - Frequently Asked Questions

CytomX Therapeutics' stock was trading at $1.03 on January 1st, 2025. Since then, CTMX stock has decreased by 42.7% and is now trading at $0.59.
View the best growth stocks for 2025 here
.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Thursday, March, 6th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.45. The biotechnology company earned $38.09 million during the quarter, compared to analysts' expectations of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative trailing twelve-month return on equity of 41.47%.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/06/2025
Today
4/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTMX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.02
High Stock Price Target
$8.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+765.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
3.41
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-570,000.00
Pretax Margin
11.89%

Debt

Sales & Book Value

Annual Sales
$138.10 million
Price / Cash Flow
N/A
Book Value
($0.71) per share
Price / Book
-0.82

Miscellaneous

Free Float
72,781,000
Market Cap
$46.46 million
Optionable
Optionable
Beta
1.05

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CTMX) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners